We are a biotechnology company developing and commercializing life-changing therapies for people living with gastrointestinal, or GI, and rare diseases. We are focused on the development and commercialization of innovative product opportunities in areas of significant unmet need, leveraging our demonstrated expertise and capabilities in GI and rare diseases.
Valuation & Multiples
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue (TTM)
$389M
▼ -15.7% YoY
Net Income (TTM)
$130M
▲ +2629.2% YoY
Op. Margin
60.15%
▲ +6.8pp YoY
ROIC
34.71%
▼ -21.3pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
$186M
▲ +22.8% YoY
Op. Cash Flow (TTM)
$186M
▲ +22.7% YoY
Net Debt
$318M
Cash & Equiv.
$79M
5Y CAGR: -5.3%
5Y CAGR: -5.3%
Continue Research
Peers
Pharmaceutical Preparations · Pick stocks to compare with IRWD
Held by ETFs
IRWD is in 35 US ETFs. The largest of them, with IRWD's weight in each:
Vanguard Health Care ETFVHT0.01%of the fund
iShares Russell 2000 Growth ETFIWO0.04%of the fund
State Street SPDR S&P Biotech ETFXBI0.12%of the fund
Schwab Fundamental U.S. Small Company ETFFNDA0.04%of the fund
iShares Biotechnology ETFIBB0.04%of the fund
Fidelity Enhanced Small Cap ETFFESM0.05%of the fund
Ironwood Pharmaceuticals (IRWD) in four numbers
Questions about Ironwood Pharmaceuticals
Is Ironwood Pharmaceuticals (IRWD) overvalued?
At $3.50, Ironwood Pharmaceuticals' price is 36% below the $5.49 a share fair value that Intrinsiqq's calculator gets from its earnings. It trades at 4.43 times earnings and 3.12 times free cash flow. The growth behind that figure is yours to set on the Intrinsic Value tab. See how to tell if a stock is overvalued.
What is Ironwood Pharmaceuticals' fair value?
Intrinsiqq's calculator puts Ironwood Pharmaceuticals' fair value at $5.49 a share. It grows earnings per share 0% a year for 5 years, applies an exit P/E of 11.2, and works back at a 10% yearly return. A 25% margin of safety gives a buy-below price of $4.12. Every input can be changed on the Intrinsic Value tab.
Is Ironwood Pharmaceuticals a high-quality business?
Ironwood Pharmaceuticals scores 52 out of 100 on Intrinsiqq's quality score, which makes it a mixed business on these measures. The score blends 8 checks computed from SEC filings. Its best check is share count change at -10.3%, and its weakest is cash flow growth at -9.3%. The Quality tab shows every check against its target.
Does Ironwood Pharmaceuticals (IRWD) pay a dividend?
No. Ironwood Pharmaceuticals (IRWD) does not pay a dividend, and no dividend payment appears anywhere in the filing history we hold. Nor has its share count fallen meaningfully over the last twelve months, so cash is kept in the business. The Dividends tab shows its cash returns.
Source: 10-Q filed 31 Jul 2026 (period ending 30 Jun 2026), SEC. Price: last close 30 Oct 2026. How this is calculated. Sector medians are approximate S&P 500 benchmarks and update periodically. Analysis, not investment advice.
Spot a number that looks wrong? Check it in IRWD's SEC filings or
Download this analysis as a PDF (Pro)
Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
Keep analysing IRWD
Create a free account and get 14 days of Premium: every stock and every tool.
- Unlimited stocks
- Stock screener
- Portfolio tracker
- Editable DCF
- Compare side by side
- Unlimited alerts
No card. Moves to Free after, unless you upgrade.
Already have an account?
Or come back tomorrow. Stocks on your watchlist are always free to view.